Literature DB >> 7977636

Small cell carcinomas of the lung express the Bcl-2 protein.

J M Ben-Ezra1, M J Kornstein, M M Grimes, G Krystal.   

Abstract

In our laboratory, we observed that a case of small cell carcinoma of the lung (SCLC) stained with a monoclonal antibody (Dako Corp., Bcl-2-124) against the Bcl-2 protein. To determine how common this reaction was, and whether it was specific for SCLC, we stained formalin-fixed, paraffin-embedded tissues from 23 cases of SCLC and 20 cases of squamous cell carcinoma of the lung for Bcl-2. Fifteen of the 23 SCLC cases stained positively for the Bcl-2 oncogene protein. In contrast, weak staining was observed in only three of the squamous cell carcinomas (chi 2-test; P = 0.001). In addition, four small cell carcinoma cell lines (H69, H146, H209, and WB) were tested by immunohistochemistry and flow cytometry for expression of this protein; all four were positive. In these and three other (H128, H432, and H510) SCLC lines, Northern blots of polyadenylated RNA revealed expression of the 6-kb Bcl-2 mRNA. Moreover, Western blots of extracts from these cell lines revealed the characteristic 26-kd band for Bcl-2 protein. In a single cell line, H82, which has previously been characterized as a variant SCLC, we failed to detect expression of the Bcl-2-specific mRNA and protein. We therefore conclude that most cases of SCLC of the lung express the Bcl-2 oncoprotein, which could play a role in the pathogenesis of this disease.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7977636      PMCID: PMC1887424     

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  26 in total

1.  bcl-2 and other genomic alterations in the prognosis of large-cell lymphoma.

Authors:  J J Yunis; M G Mayer; M A Arnesen; D P Aeppli; M M Oken; G Frizzera
Journal:  N Engl J Med       Date:  1989-04-20       Impact factor: 91.245

2.  c-myc expression correlates with suppression of c-kit protooncogene expression in small cell lung cancer cell lines.

Authors:  H Plummer; J Catlett; J Leftwich; B Armstrong; P Carlson; T Huff; G Krystal
Journal:  Cancer Res       Date:  1993-09-15       Impact factor: 12.701

3.  Molecular analysis of the t(14;18) chromosomal translocation in malignant lymphomas.

Authors:  L M Weiss; R A Warnke; J Sklar; M L Cleary
Journal:  N Engl J Med       Date:  1987-11-05       Impact factor: 91.245

4.  Cloning and structural analysis of cDNAs for bcl-2 and a hybrid bcl-2/immunoglobulin transcript resulting from the t(14;18) translocation.

Authors:  M L Cleary; S D Smith; J Sklar
Journal:  Cell       Date:  1986-10-10       Impact factor: 41.582

5.  The bcl-2 gene is rearranged in many diffuse B-cell lymphomas.

Authors:  A C Aisenberg; B M Wilkes; J O Jacobson
Journal:  Blood       Date:  1988-04       Impact factor: 22.113

6.  Expression of the bcl-2 oncogene protein is not specific for the 14;18 chromosomal translocation.

Authors:  F Pezzella; A G Tse; J L Cordell; K A Pulford; K C Gatter; D Y Mason
Journal:  Am J Pathol       Date:  1990-08       Impact factor: 4.307

7.  Purification of biologically active globin messenger RNA by chromatography on oligothymidylic acid-cellulose.

Authors:  H Aviv; P Leder
Journal:  Proc Natl Acad Sci U S A       Date:  1972-06       Impact factor: 11.205

8.  Expression in non-Hodgkin's lymphoma of the bcl-2 protein associated with the t(14;18) chromosomal translocation.

Authors:  B Y Ngan; Z Chen-Levy; L M Weiss; R A Warnke; M L Cleary
Journal:  N Engl J Med       Date:  1988-06-23       Impact factor: 91.245

9.  Isolation and characterization of full-length cDNA clones for human alpha-, beta-, and gamma-actin mRNAs: skeletal but not cytoplasmic actins have an amino-terminal cysteine that is subsequently removed.

Authors:  P Gunning; P Ponte; H Okayama; J Engel; H Blau; L Kedes
Journal:  Mol Cell Biol       Date:  1983-05       Impact factor: 4.272

10.  Multiple mechanisms for transcriptional regulation of the myc gene family in small-cell lung cancer.

Authors:  G Krystal; M Birrer; J Way; M Nau; E Sausville; C Thompson; J Minna; J Battey
Journal:  Mol Cell Biol       Date:  1988-08       Impact factor: 4.272

View more
  34 in total

1.  Moloney murine leukemia virus-induced tumors show altered levels of proapoptotic and antiapoptotic proteins.

Authors:  C Bonzon; H Fan
Journal:  J Virol       Date:  2000-09       Impact factor: 5.103

Review 2.  Small Cell Lung Cancer: Can Recent Advances in Biology and Molecular Biology Be Translated into Improved Outcomes?

Authors:  Paul A Bunn; John D Minna; Alexander Augustyn; Adi F Gazdar; Youcef Ouadah; Mark A Krasnow; Anton Berns; Elisabeth Brambilla; Natasha Rekhtman; Pierre P Massion; Matthew Niederst; Martin Peifer; Jun Yokota; Ramaswamy Govindan; John T Poirier; Lauren A Byers; Murry W Wynes; David G McFadden; David MacPherson; Christine L Hann; Anna F Farago; Caroline Dive; Beverly A Teicher; Craig D Peacock; Jane E Johnson; Melanie H Cobb; Hans-Guido Wendel; David Spigel; Julien Sage; Ping Yang; M Catherine Pietanza; Lee M Krug; John Heymach; Peter Ujhazy; Caicun Zhou; Koichi Goto; Afshin Dowlati; Camilla Laulund Christensen; Keunchil Park; Lawrence H Einhorn; Martin J Edelman; Giuseppe Giaccone; David E Gerber; Ravi Salgia; Taofeek Owonikoko; Shakun Malik; Niki Karachaliou; David R Gandara; Ben J Slotman; Fiona Blackhall; Glenwood Goss; Roman Thomas; Charles M Rudin; Fred R Hirsch
Journal:  J Thorac Oncol       Date:  2016-01-30       Impact factor: 15.609

3.  Decreased mitochondrial priming determines chemoresistance of colon cancer stem cells.

Authors:  S Colak; C D Zimberlin; E Fessler; L Hogdal; P R Prasetyanti; C M Grandela; A Letai; J P Medema
Journal:  Cell Death Differ       Date:  2014-03-28       Impact factor: 15.828

4.  Phase I study of Navitoclax (ABT-263), a novel Bcl-2 family inhibitor, in patients with small-cell lung cancer and other solid tumors.

Authors:  Leena Gandhi; D Ross Camidge; Moacyr Ribeiro de Oliveira; Philip Bonomi; David Gandara; Divis Khaira; Christine L Hann; Evelyn M McKeegan; Elizabeth Litvinovich; Philip M Hemken; Caroline Dive; Sari H Enschede; Cathy Nolan; Yi-Lin Chiu; Todd Busman; Hao Xiong; Andrew P Krivoshik; Rod Humerickhouse; Geoffrey I Shapiro; Charles M Rudin
Journal:  J Clin Oncol       Date:  2011-01-31       Impact factor: 44.544

5.  Interferon alpha plus 13-cis-retinoic acid modulation of BCL-2 plus paclitaxel for recurrent small-cell lung cancer (SCLC): an Eastern Cooperative Oncology Group study (E6501).

Authors:  Rathi N Pillai; Joseph Aisner; Suzanne E Dahlberg; John S Rogers; Robert S DiPaola; Seena Aisner; Suresh S Ramalingam; Joan H Schiller
Journal:  Cancer Chemother Pharmacol       Date:  2014-05-24       Impact factor: 3.333

6.  Bcl2 is not required for the development and maintenance of leukemia stem cells in mice.

Authors:  Inés González-Herrero; Carolina Vicente-Dueñas; Alberto Orfao; Teresa Flores; Rafael Jiménez; César Cobaleda; Isidro Sánchez-García
Journal:  Carcinogenesis       Date:  2010-03-18       Impact factor: 4.944

7.  Combined MET inhibition and topoisomerase I inhibition block cell growth of small cell lung cancer.

Authors:  Cleo E Rolle; Rajani Kanteti; Mosmi Surati; Suvobroto Nandi; Immanuel Dhanasingh; Soheil Yala; Maria Tretiakova; Qudsia Arif; Todd Hembrough; Toni M Brand; Deric L Wheeler; Aliya N Husain; Everett E Vokes; Ajit Bharti; Ravi Salgia
Journal:  Mol Cancer Ther       Date:  2013-12-10       Impact factor: 6.261

8.  Overexpression of DDB2 enhances the sensitivity of human ovarian cancer cells to cisplatin by augmenting cellular apoptosis.

Authors:  Bassant M Barakat; Qi-En Wang; Chunhua Han; Keisha Milum; De-Tao Yin; Qun Zhao; Gulzar Wani; El-Shaimaa A Arafa; Mohamed A El-Mahdy; Altaf A Wani
Journal:  Int J Cancer       Date:  2010-08-15       Impact factor: 7.396

Review 9.  Cellular and molecular biology of small cell lung cancer: an overview.

Authors:  Niki Karachaliou; Sara Pilotto; Chiara Lazzari; Emilio Bria; Filippo de Marinis; Rafael Rosell
Journal:  Transl Lung Cancer Res       Date:  2016-02

10.  Combination with vorinostat overcomes ABT-263 (navitoclax) resistance of small cell lung cancer.

Authors:  Wataru Nakajima; Kanika Sharma; Mark A Hicks; Ngoc Le; Rikiara Brown; Geoffrey W Krystal; Hisashi Harada
Journal:  Cancer Biol Ther       Date:  2016       Impact factor: 4.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.